Држава: Сједињене Америчке Државе
Језик: Енглески
Извор: NLM (National Library of Medicine)
FENOFIBRATE (UNII: U202363UOS) (FENOFIBRIC ACID - UNII:BGF9MN2HU1)
Proficient Rx LP
ORAL
PRESCRIPTION DRUG
Fenofibrate tablet USP is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate tablet USP is also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Fenofibrate at a dose equivalent to 160 mg of fenofibrate tablet USP was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with t
Fenofibrate tablets USP are available in two strengths: Fenofibrate tablets USP, 54 mg are yellow, round, biconvex, film coated tablets debossed with "LU" on one side and "J41" on the other side. They are available as follows: Bottles of 90 NDC 68180-362-09 Bottles of 500 NDC 68180-362-02 Bottles of 1000 NDC 68180-362-03 Carton of 100 (10 x 10) Unit-dose Tablets NDC 68180-362-13 Fenofibrate tablets USP, 160 mg are white to off-white oval shaped, biconvex film coated tablets, debossed with "LU" on one side and "J42" on the other side. They are available as follows: Bottles of 90 NDC 68180-363-09 Bottles of 500 NDC 68180-363-02 Bottles of 1000 NDC 68180-363-03 Carton of 100 (10 x 10) Unit-dose Tablets NDC 68180-363-13 Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from moisture. Keep out of reach of children.
Abbreviated New Drug Application
FENOFIBRATE- FENOFIBRATE TABLET PROFICIENT RX LP ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE FENOFIBRATE TABLET SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR FENOFIBRATE TABLET. FENOFIBRATE TABLETS USP, 54 MG AND 160 MG, FOR ORAL USE INITIAL U.S. APPROVAL: 1993 RECENT MAJOR CHANGES Warnings and Precautions, Hypersensitivity Reactions (5.9) 05/2018 INDICATIONS AND USAGE Fenofibrate tablet USP is a peroxisome proliferator-activated receptor (PPAR) alpha agonist indicated as an adjunct to diet: • • Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus (5.1). DOSAGE AND ADMINISTRATION • • • • • DOSAGE FORMS AND STRENGTHS • CONTRAINDICATIONS • • • • • WARNINGS AND PRECAUTIONS • • • • • • ADVERSE REACTIONS Adverse reactions > 2% and at least 1% greater than placebo: Abnormal liver tests, increased AST, increased ALT, increased CPK, and rhinitis (6). TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT LUPIN PHARMACEUTICALS, INC. AT 1-800-399-2561 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH DRUG INTERACTIONS • • • USE IN SPECIFIC POPULATIONS • • SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 11/2019 To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (1.1). For treatment of adult patients with severe hypertriglyceridemia (1.2). Primary hypercholesterolemia or mixed dyslipidemia: Initial dose of 160 mg once daily (2.2). Severe hypertriglyceridemia: Initial dose of 54 to 160 mg once daily. Maximum dose is 160 mg (2.3). Renally impaired patients: Initial dose of 54 mg once daily (2.4). Geriatric patients: Select the dose on the basis of renal function (2.5). Should be given with meals (2.1). Oral Tablets: 54 mg and 160 mg (3). Severe renal dysfunction, including dialysis patients (4, 8.6, 12.3). Active live Прочитајте комплетан документ